An abnormal CD34+ myeloid/CD34+ lymphoid ratio at the end of chemotherapy predicts relapse in patients with acute myeloid leukemia

Communications in Clinical Cytometry

Volumn 38, Issue 2, 1999, Pages 70-75

  Martinez A ^a   San Miguel, Jesus F ^a   Vidriales, M B ^a   Ciudad, J ^b   Caballero, M D ^a   Lopez Berges M C ^a   Moro, M J ^c   Calmuntia, M J ^d   Ortega, F ^e   Orfao, A ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c Virgen Blanca   (Spain)

^d General Social Security Hospital   (Spain)

^e HOSPITAL RÍO CARRIÓN   (Spain)

Author keywords

AML; CD34 stem cells; Prognostic influence

Indexed keywords

CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MERCAPTOPURINE; RETINOIC ACID; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; SCHOOL CHILD; STEM CELL;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CHILD; FEMALE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; LYMPHOCYTES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 0345621632     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19990415)38:2<70::AID-CYTO4>3.0.CO;2-S     Document Type: Article

References (17)

1. Campana D, Pui CH. Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 1995;85:1416-1434.
2. Coustan-Smith E, Behm FG, Hurwitz CA, Rivera GK, Campana D. N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 1993;7:853-858.
3. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Arrisati G, Rambaldi A, Arcese W, Petti MC, Meloni G. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia. Lancet 1992;340:1437-1438.
4. Macedo A, Orfao A, Gonzalez M, Vidriales MB, López-Berges MC, Martínez A, San Miguel JF. Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. Leukemia 1995;9:993-998.
5. Macedo A, Orfao A, Vidriales MB, López Berges MC, González M, Caballero MD, Ramos F, Martinez M, San Miguel JF. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995;70:189-194.
6. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akasi T, Takenaka K, Mizuno S, Gondo H, Okamura T, Dohy H, Niho Y. Persistence of multipotent progenitors expression AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996;87:4789-4796.
7. Reading CL, Estey EH, Huh YO, Claxton DF, Sánchez G, Terstappen LW, O'Brien MC, Baron S, Deisseroth AB. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 1993;81:3083-3090.
8. San Miguel JF, Gonzalez M, Orfao A. Minimal residual disease in acute myeloid malignancies. In: Degos L, Linch D, Lowenberg B, editors. Textbook of malignant haematology. Martin Dunitz Ltd. London, 1999; p 871-893.
9. van Dongen JJ, Breit TM, Adriaansen HJ, Beishuizen A, Hooijkaas H. Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia 1992;6(Suppl 1):47-59.
10. van Dongen JJ, San Miguel JF. Techniques for detection of minimal residual disease in leukaemia patients. In: meet the expert sessions of the second EHA. Oxford: Blackwell Science Ltd.; 1996. p 39.
11. Weiner RS, Oblon DJ, Gross MA. Stem cell factor defects after intensive cytoreductive therapy for AML. Exp Hematol 1990;75:340-345.
12. Cheson BD, Cassileth PA, Head DR, Chiller CA, Bennet JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
13. Macedo A, Orfao A, Ciudad J, González M, Vidriales B, López-Berges C, Martínez A, Landolfi C, Cañizo C, San Miguel JF. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995;9: 1896-1901.
14. Macedo A, Orfao A, Martinez A, Vidriales MB, Valverde B, López Berges MC, San Miguel JF. Immunophenotype of c-kit cells in normal human bone marrow: implications for the detection of minimal residual disease in AML. Br J Haematol 1995;89:338-341.
15. Terstappen LW, Mickaels RA, Dost R, Loken MR. Increased light scattering resolution facilitates multidimensional flow cytometry analysis. Cytometry 1990;11:506-512.
16. Dixon WJ. Biomedical-Data Package: Statistical Software. University of California, 1993.
17. San Miguel JF, Martínez A, Macedo A, Vidriales B, López-Berges MC, González M, Caballero MD, García Marcos F, Ramos F, Fernández Calvo J, Calmuntia MJ, Díaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997;90: 2465-2470.